NASDAQ:JAN JanOne (JAN) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free JAN Stock Alerts $3.08 -0.04 (-1.28%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$3.00▼$3.1750-Day Range$2.36▼$5.1052-Week Range$0.22▼$5.26Volume34,060 shsAverage Volume198,360 shsMarket Capitalization$27.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get JanOne alerts: Email Address Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About JanOne Stock (NASDAQ:JAN)JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.Read More JAN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JAN Stock News HeadlinesMay 28, 2024 | prnewswire.comALT 5 Sigma, a wholly-owned subsidiary of JanOne to Present at the iFX Expo, the World's largest online trading conference and tradeshowMay 16, 2024 | finance.yahoo.comJanOne Inc. (JAN) Stock Price, News, Quote & History - Yahoo FinanceMay 16, 2024 | prnewswire.comJanOne Closes Acquisition of ALT 5 Sigma Inc., a Leading Next Generation Blockchain FintechMay 13, 2024 | msn.comWhy Tevogen Bio Holdings Stock Is Moving Higher TodayMay 13, 2024 | markets.businessinsider.comJanOne To Buy Block Chain Fintech Provider ALT 5 Sigma In All-stock Deal; JAN Up In Pre-marketMay 10, 2024 | finance.yahoo.comJanOne to Acquire ALT 5 Sigma Inc., a Leading Next Generation Blockchain Financial Technology ProviderMay 3, 2024 | markets.businessinsider.comJAN Stock Earnings: JanOne Reported Results for Q1 2024March 15, 2024 | prnewswire.comJanOne Regains Compliance with Nasdaq's Listing RequirementsFebruary 13, 2024 | msn.comWhy ZoomInfo Technologies Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving PremarketFebruary 9, 2024 | msn.comJanOne, Inc. Revises Promissory Notes and Issues New DebtDecember 23, 2023 | morningstar.comJanOne Inc JANNovember 9, 2023 | msn.comWhy Is Assertio (ASRT) Stock Down 39% Today?November 7, 2023 | nj.comN.J. general election results 2023: Morris CountySeptember 21, 2023 | finance.yahoo.comJanOne to Present at the Dawson James 8th Annual Investment ConferenceAugust 31, 2023 | finance.yahoo.comJanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment ConferenceAugust 29, 2023 | marketwatch.comJanOne Shares Jump 16% After Obtaining U.S. Patent for Jan123 to Treat Chronic PainAugust 29, 2023 | finance.yahoo.comJanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic PainAugust 25, 2023 | finance.yahoo.comJanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual MeetingAugust 22, 2023 | finance.yahoo.comJanOne Technologies Announces Closing of Registered Direct Offering Priced At-The-Market under Nasdaq RulesAugust 18, 2023 | finance.yahoo.comJanOne Technologies Announces Registered Direct Offering Priced At-The-Market under Nasdaq RulesAugust 18, 2023 | finance.yahoo.comJanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual MeetingJune 28, 2023 | markets.businessinsider.comJanOne Files Intl Patent Application For Low Dose Naltrexone For Chronic PainJune 28, 2023 | finance.yahoo.comJanOne files international patent application for methods of using low dose naltrexone to treat chronic painApril 18, 2023 | finance.yahoo.comJanOne Completes Pre-IND Meeting with FDA on Jan123April 13, 2023 | finance.yahoo.comJanOne to Present Data On Its Two Non-Opioid Drug Candidates at The Appalachian Region Spine and Pain Meeting on Drug Development Programs to Treat Pain on April 15, 2023See More Headlines Receive JAN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for JanOne and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/03/2024Today6/02/2024Next Earnings (Estimated)8/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:JAN CUSIPN/A CIK862861 Webwww.janone.com Phone(702) 997-5968Fax952-930-1800Employees199Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,810,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-359.71% Return on Assets-70.26% Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick Ratio0.15 Sales & Book Value Annual Sales$39.61 million Price / Sales0.70 Cash FlowN/A Price / Cash FlowN/A Book Value($0.47) per share Price / Book-6.55Miscellaneous Outstanding Shares8,980,000Free Float8,707,000Market Cap$27.66 million OptionableNot Optionable Beta2.04 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Tony Isaac (Age 70)President, CEO, Corporate Secretary & Director Comp: $625.32kMr. Virland A. Johnson CPA (Age 61)Chief Financial Officer Comp: $250.32kDr. Tony Giordano Ph.D.Chief Scientific OfficerMs. Cyndy L. JanzigDirector of Human ResourcesDr. Douglas FlanaganChief Formulation AdvisorKey CompetitorsBed Bath & BeyondNASDAQ:BBBYThe Container Store GroupNYSE:TCSImmunicNASDAQ:IMUXCervoMedNASDAQ:CRVOVistagen TherapeuticsNASDAQ:VTGNView All Competitors JAN Stock Analysis - Frequently Asked Questions How have JAN shares performed in 2024? JanOne's stock was trading at $0.5550 at the beginning of 2024. Since then, JAN shares have increased by 455.0% and is now trading at $3.08. View the best growth stocks for 2024 here. Are investors shorting JanOne? JanOne saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 262,100 shares, an increase of 46.3% from the April 30th total of 179,200 shares. Based on an average daily volume of 261,000 shares, the short-interest ratio is currently 1.0 days. View JanOne's Short Interest. When is JanOne's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 20th 2024. View our JAN earnings forecast. How were JanOne's earnings last quarter? JanOne Inc. (NASDAQ:JAN) released its quarterly earnings data on Friday, May, 3rd. The company reported ($0.34) earnings per share (EPS) for the quarter. How do I buy shares of JanOne? Shares of JAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:JAN) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JanOne Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
